Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Vir biotechnology, inc. symbols : Glaxf save search
US Food and Drug Administration Revises Emergency Use Authorization for Sotrovimab Due to Omicron BA.2 Subvariant
Published: 2022-03-25 (Crawled : 21:00) - biospace.com/
GLAXF | News | $20.305 -14.18% 630
|
Health Technology
|
| O: 4.57%
H: 0.0%
C: -3.26%
GSK | News | $41.24 1.6% 0.0% 2.3M
|
Health Technology
|
| O: -0.02%
H: 0.0%
C: 0.0%
XNCR | $18.35 0.77% 0.76% 480K
|
Health Technology
|
| O: -0.7%
H: 1.94%
C: -1.47%
VIR | $8.13 0.37% 0.37% 770K
|
Health Technology
|
| O: -1.07%
H: 0.8%
C: -12.62%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: 0.0%
drug food authorization emergency use authorization
GSK and Vir Submit Emergency Use Authorization Application to FDA for Intramuscular Administration of Sotrovimab for the Early Treatment of COVID-19
Published: 2022-01-13 (Crawled : 15:30) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
GSK | News | $41.24 1.6% 0.0% 2.3M
|
Health Technology
|
| O: 0.29%
H: 0.0%
C: 0.0%
XNCR | $18.35 0.77% 0.76% 480K
|
Health Technology
|
| O: 0.38%
H: 1.12%
C: -1.31%
VIR | $8.13 0.37% 0.37% 770K
|
Health Technology
|
| O: 1.05%
H: 1.98%
C: -6.88%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -0.74%
H: 0.0%
C: 0.0%
covid-19 treatment fda application covid authorization merge emergency use authorization
Xevudy (Sotrovimab) Granted Marketing Authorization by the European Commission for the Early Treatment of COVID-19
Published: 2021-12-17 (Crawled : 13:30) - globenewswire.com
GLAXF | News | $20.305 -14.18% 630
|
Health Technology
|
| O: 2.36%
H: 0.46%
C: 0.46%
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.48%
H: 0.0%
C: 0.0%
GSK | News | $41.24 1.6% 0.0% 2.3M
|
Health Technology
|
| O: 0.86%
H: 0.0%
C: 0.0%
XNCR | $18.35 0.77% 0.76% 480K
|
Health Technology
|
| O: -0.45%
H: 0.0%
C: 0.0%
VIR | $8.13 0.37% 0.37% 770K
|
Health Technology
|
| O: -4.59%
H: 0.0%
C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.22%
H: 0.0%
C: 0.0%
covid-19 treatment europe granted covid authorization grant
Anxious World Waits As Covid Vaccine Makers Address Omicron Variant
Published: 2021-12-07 (Crawled : 14:00) - prnewswire.com
GLAXF | News | $20.305 -14.18% 630
|
Health Technology
|
| O: 5.22%
H: 0.0%
C: -1.25%
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: 2.13%
H: 0.0%
C: 0.0%
GSK | News | $41.24 1.6% 0.0% 2.3M
|
Health Technology
|
| O: 0.14%
H: 0.0%
C: 0.0%
VIR | $8.13 0.37% 0.37% 770K
|
Health Technology
|
| O: -6.42%
H: 8.6%
C: 8.45%
SRNE | $0.015 -8.85% 140K
|
Health Technology
|
| O: 6.57%
H: 14.77%
C: 11.21%
RDHL | $0.4277 -3.32% -3.44% 470K
|
Health Technology
|
| O: 0.37%
H: 10.37%
C: 9.63%
covid vaccine
Preclinical Studies Demonstrate Sotrovimab Retains Activity Against the Full Combination of Mutations in the Spike Protein of the Omicron SARS-CoV-2 Variant
Published: 2021-12-07 (Crawled : 09:00) - globenewswire.com
GLAXF | News | $20.305 -14.18% 630
|
Health Technology
|
| O: 5.22%
H: 0.0%
C: -1.25%
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 3.63%
H: 0.0%
C: 0.0%
GSK | News | $41.24 1.6% 0.0% 2.3M
|
Health Technology
|
| O: 0.14%
H: 0.0%
C: 0.0%
XNCR | $18.35 0.77% 0.76% 480K
|
Health Technology
|
| O: -2.12%
H: 4.74%
C: 2.8%
VIR | $8.13 0.37% 0.37% 770K
|
Health Technology
|
| O: -6.42%
H: 8.6%
C: 8.45%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: 0.0%
preclinical sars-cov-2 pre-clinical
Preclinical Data Demonstrate Sotrovimab Retains Activity Against Key Omicron Mutations, New SARS-CoV-2 Variant
Published: 2021-12-02 (Crawled : 08:00) - globenewswire.com
GLAXF | News | $20.305 -14.18% 630
|
Health Technology
|
| O: -0.05%
H: 0.0%
C: -1.97%
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.18%
H: 0.0%
C: 0.0%
GSK | News | $41.24 1.6% 0.0% 2.3M
|
Health Technology
|
| O: 0.58%
H: 0.5%
C: -0.36%
VIR | $8.13 0.37% 0.37% 770K
|
Health Technology
|
| O: 20.02%
H: 0.19%
C: -12.53%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -0.19%
H: 0.0%
C: 0.0%
preclinical sars-cov-2 pre-clinical
GSK and Vir Biotechnology Announce United States Government Agreements to Purchase Sotrovimab, a COVID-19 Treatment
Published: 2021-11-17 (Crawled : 12:00) - globenewswire.com
GLAXF | News | $20.305 -14.18% 630
|
Health Technology
|
| O: 1.43%
H: 2.31%
C: 2.27%
GSK | News | $41.24 1.6% 0.0% 2.3M
|
Health Technology
|
| O: -0.28%
H: 0.0%
C: 0.0%
VIR | $8.13 0.37% 0.37% 770K
|
Health Technology
|
| O: 9.97%
H: 4.0%
C: -6.28%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: 0.0%
covid treatment biotech technology iot covid-19
Primary endpoint met in COMET-TAIL Phase 3 trial evaluating intramuscular administration of sotrovimab for early treatment of COVID-19
Published: 2021-11-12 (Crawled : 13:00) - biospace.com/
GLAXF | News | $20.305 -14.18% 630
|
Health Technology
|
| O: 1.8%
H: 0.0%
C: -0.31%
GSK | News | $41.24 1.6% 0.0% 2.3M
|
Health Technology
|
| O: 0.93%
H: 0.0%
C: 0.0%
VIR | $8.13 0.37% 0.37% 770K
|
Health Technology
|
| O: 4.66%
H: 0.0%
C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -0.66%
H: 0.0%
C: 0.0%
covid treatment phase 3 trial
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News M | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.